Intelligent Bio Solutions Expands U.S. Forensic Market Presence, Seeks FDA Clearance for Breakthrough Fingerprint Drug Testing
Company continues to actively pursue FDA clearance in connection with planned expansion into broader U.S. markets in 2025
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced an update on its growing footprint in the U.S. Forensic Use Only Market through its strategic partnership with SMARTOX, a Texas-based leader in drug and alcohol screening services.
SMARTOX supports clients across corrections, drug courts, rehabilitation centres, and other forensic environments. It has deployed over 50 Intelligent Fingerprinting Drug Screening Readers and facilitated over 7,000 screening tests, including more than 1,500 tests in 2024 alone, highlighting accelerated demand for non-invasive, rapid testing in forensic settings. INBS' drug screening technology is credited with reducing reliance on invasive methods such as urine or saliva collection, while delivering rapid and reliable results directly linked to the individual tested.
As adoption grows in the U.S. Forensic Use Only market, INBS continues to actively pursue FDA clearance for its opiate test system for codeine. This effort aims to enable expansion into broader U.S. markets this year, including workplace drug testing, using its innovative fingerprint sweat-based testing technology.
"We have partnered with SMARTOX to expand access to our fingerprint drug screening system across key forensic settings such as criminal justice," said Doug Heath, Vice President of Global Sales at Intelligent Bio Solutions. "SMARTOX's commitment to innovation aligns with our mission to transform drug testing through intelligent, non-invasive technologies."
SMARTOX is known for its expertise, innovation, and customer-focused approach to drug testing. Its portfolio includes DOT compliance solutions, instant and lab-based testing, and advanced technologies, including INBS' Intelligent Fingerprinting Drug Screening System, which enables hygienic, non-invasive drug screening in under ten minutes using fingerprint sweat. In addition to serving clients across the U.S., SMARTOX reaches international markets through its distribution network, including Europe, Latin America, New Zealand, and Australia.
"Our clients consistently report that the Intelligent Fingerprinting Drug Screening System improves efficiency, enhances user dignity, and simplifies operations," said Duffy Nabors, Vice President of Sales and Marketing at SMARTOX. "They value its speed, ease of use, and non-invasiveness, along with the ability to eliminate gender-specific staff requirements and special facilities. These benefits help our clients reduce turnaround times, lower costs, and eliminate logistical complexities, improving the overall testing experience."
About SMARTOX
SMARTOX, founded in 2012, is a U.S.-based provider of drug and alcohol testing products and services. It offers a comprehensive portfolio supporting a wide range of settings, including healthcare, justice, corporate, and education. SMARTOX is committed to delivering advanced technology and exceptional results, providing fully integrated services encompassing design, customer service, and administrative support for its product line. The company's footprint spans the U.S. and international markets. SMARTOX is actively scaling its presence in forensic testing markets through new investments, pilot programs, and expanded jurisdictional coverage.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company's current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.
For more information, visit: https://www.ibs.inc
Forward-Looking Statements:
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions' public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact: Intelligent Bio Solutions Inc. info@ibs.inc LinkedIn | Twitter
Investor & Media Contact: Valter Pinto, Managing Director KCSA Strategic Communications PH: (212) 896-1254 INBS@kcsa.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Strategy Incorporated (MSTR) Announces Q2 2025 Results
MicroStrategy Incorporated, doing business as, Strategy Incorporated (NASDAQ:MSTR) is one of the Reddit Stocks with the Highest Upside Potential. On July 31, the company announced its Q2 2025 results, with net income coming at $10.0 billion. In Q2 2025 and into July, Strategy Incorporated (NASDAQ:MSTR) delivered another period of strong execution and growth. The company expanded its bitcoin holdings to 628,791 bitcoins, garnered more than $10 billion via its ATM programs and IPOs, and witnessed increased institutional and retail demand for the securities. A software engineer wearing a headset, collaborating with a remote team on a project. Strategy Incorporated (NASDAQ:MSTR)'s operating income for Q2 2025 came in at ~$14.03 billion, a 7,106.4% increase YoY. Operating income consisted of an unrealized gain on the company's digital assets, which amounted to $14.0 billion. Through July 29, the company's Bitcoin holdings make up for 3% of all the Bitcoin ever to be in existence. This places the company as the most dominant player in the Bitcoin Treasury Company space. Strategy Incorporated (NASDAQ:MSTR) raised an impressive $18.3 billion in capital YTD, accounting for 81% of the total capital it raised in all of last year combined. Greenlight Capital, an investment management firm, released its Q4 2024 investor letter. Here is what the fund said: 'There is an open debate as to whether Bitcoin will at some point enter the mainstream as an official currency. In fact, there is a bill before Congress for the U.S. to establish a 'Strategic Bitcoin Reserve' and buy one million Bitcoins over five years. The bill's purpose appears to be the use of public funds to ramp up the price of Bitcoin, thereby enhancing the wealth of existing Bitcoin holders. This seems a dubious use of taxpayer funds, but the new administration has a lot of Bitcoin-owning supporters, so it might happen. More likely, cooler heads will decide that the government should not borrow another trillion dollars in the bond market to speculate in Bitcoin and that there is, in fact, nothing strategic about doing so. While we acknowledge the potential of MSTR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
29 minutes ago
- Yahoo
Bank of America Securities Reiterates Buy Rating on Crocs (CROX) Stock
Crocs, Inc. (NASDAQ:CROX) is one of the Reddit Stocks with the Highest Upside Potential. On August 8, Bank of America Securities analyst Christopher Nardone reiterated a 'Buy' rating on the company's stock and set a price objective of $99.00. The analyst's rating is backed by a combination of factors demonstrating potential for future growth amidst the current challenges. As per the analyst, while Q3 2025 guidance was disappointing, there remains an optimistic outlook for Crocs, Inc. (NASDAQ:CROX)'s fundamentals to witness improvement beyond this period. A busy retail store full of customers trying on a wide range of footwear. Furthermore, the international segment demonstrated a promising growth in Q2 2025, and the analyst opines that a low double-digit growth rate remains achievable in the upcoming quarters. Even though there are short-term pressures due to the tariffs and changes in product mix, the analyst opines that the gross margin is expected to stay strong because of Crocs, Inc. (NASDAQ:CROX)'s emphasis on controlling promotions. This strategic approach is expected to support a healthy FCF profile, added Nardone. While North American sales are projected to encounter challenges, the analyst anticipates gradual improvement on the back of new product innovations as well as strategic adjustments to offset tariff impacts. Artisan Partners, an investment management company, released its Q4 2024 investor letter. Here is what the fund said: 'Among our top detractors were Halozyme, Crocs, Inc. (NASDAQ:CROX) and Novanta. Crocs designs, develops, manufactures and distributes casual footwear and accessories for men, women and children. The company invented the molded plastic clog in 2002 and turned it into a multibillion-dollar (USD) global revenue producer. We believe expansion opportunities outside the US, demand from new product introductions (including from recently acquired Hey Dude) and distribution pushes within the direct-to-consumer and wholesale channels will drive greater-than-expected revenue growth. We had expected the performance of its HeyDude brand to have already bottomed, but forward guidance continues to indicate its turnaround efforts, driven by a new divisional leader, will take longer than expected. We maintained our position as we believe the market underappreciates the longer term profit cycle.' While we acknowledge the potential of CROX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29 minutes ago
- Yahoo
Better Technology Stock: Nvidia vs. Palantir
Key Points Nvidia is now the most valuable publicly traded company in the world, and all signs point to another great earnings report this month. Palantir Technologies is the fastest-growing company in the S&P 500. 10 stocks we like better than Nvidia › Semiconductor giant Nvidia (NASDAQ: NVDA) and artificial intelligence (AI) kingpin Palantir Technologies (NASDAQ: PLTR) are two of the most compelling technology stocks in the market. Nvidia harnessed demand for its graphics processing units (GPUs) to become the biggest company in the world, with a $4.4 trillion market capitalization. Palantir, meanwhile, is using its artificial intelligence platform to fundamentally change how governments and commercial businesses operate. The stock is up more than 500% in the last year and is the best-performing stock in the S&P 500. In my view, you can't go wrong with either of these tech stocks. But in a one-on-one matchup, which comes out on top? Let's look at both companies before rendering a verdict. Nvidia Nvidia's GPUs are the engine behind this mammoth company. While they used to be best known for providing the graphics in computers, now GPUs are commonly used by companies that are building massive data centers to run artificial intelligence-powered platforms, including large language models needed for generative AI. Nvidia has the lion's share of this business, with Jon Peddie Research estimating that it has roughly 92% of the market share. And as Nvidia is expecting spending on data centers to accelerate from $250 billion in 2023 to $1 trillion annually by 2028, there's a massive opportunity at hand. In addition, major tech companies like Microsoft, Alphabet, and Meta Platforms are spending heavily and are even increasing their capital expenditure spending on their data centers. That's why I'm expecting a solid earnings report from Nvidia when it reports its earnings for the current quarter, and why I'm expecting the stock to pop yet again after the numbers are released. Palantir Technologies Palantir got its start a little more than 20 years ago as a data mining company to provide real-time analytics and insights. As a government contractor, it's long been valued by the military for its analytic technology that helps commanders make real-time decisions in battle. To the public eye, Palantir largely flew under the radar for years until in 2011, when it was credited for helping U.S. forces find and eliminate Sept. 11 mastermind Osama bin Laden. Palantir works by drawing information from many sources, such as satellite imagery. By sifting through and digesting that information, it can perform instantaneous analysis that can help governments function. According to its CEO, Alex Karp, "Palantir was founded on the belief that the United States, its allies, and partners should harness the most advanced technical capabilities for their defense and prosperity." As its capabilities expanded through the launch of its generative AI-powered Artificial Intelligence Platform (AIP), Palantir is quickly bringing in additional non-military government contracts. It has new contracts with the Federal Aviation Administration, the Centers for Disease Control and Prevention, the State Department, and the Internal Revenue Service. In the company's just-released second quarter earnings report, U.S. government revenue increased 53% in the last year, reaching $426 million. Commercial revenue is growing even faster, up 93% in the second quarter on a year-over-year basis and reaching $306 million. Clients include Walgreens Boots Alliance, AT&T, General Mills, United Airlines, and others, and Palantir is doing everything from making manufacturing more efficient to managing supply chains and helping companies scale. Palantir closed 157 deals in the second quarter valued at more than $1 million, with 66 of them more than $5 million and 42 of them at least $10 million. As more companies bring Palantir's platform online and share how they are improving their businesses, Palantir's platform will become a must-have for many institutions. The verdict I'm not gonna lie. This is a tough one. I love both of these companies, and I think both are destined to increase. But if I have to choose one, then the valuations of both companies will break the tie. At the time of this writing, Nvidia is richly valued both in its price-to-earnings (P/E) ratio of 59 and its forward P/E of 42, but Palantir comes in at an unhealthy 623 and 288, respectively. The price-to-sales ratio, which compares market capitalization to revenue, is arguably an even more accurate measurement as both of these companies are pouring profits back into the business. And Nvidia is by far the strongest there, too. So, my winner in this hypothetical battle is Nvidia by a nose. But both stocks are great ones to have, and they'll both anchor my portfolio for the foreseeable future. Should you buy stock in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Patrick Sanders has positions in Nvidia and Palantir Technologies. The Motley Fool has positions in and recommends Alphabet, Meta Platforms, Microsoft, Nvidia, and Palantir Technologies. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Better Technology Stock: Nvidia vs. Palantir was originally published by The Motley Fool Sign in to access your portfolio
